FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

AbbVie sNDA for Imbruvica/Rituximab Combo

[ Price : $8.95]

AbbVie files a supplemental NDA for Imbruvica (ibrutinib) in combination with rituximab for the first-line treatment of younger pa...

FDA Withdraws Haemonetics ANDA

[ Price : $8.95]

Federal Register notice: FDA withdraws approval of a Haemonetics ANDA for Anticoagulant Citrate Dextrose SolutionA, USP, in plasti...

Info Collection on Generic Drug Correspondence

[ Price : $8.95]

Federal Register notice: FDA submits to OMB an information collection revision entitled for Controlled Correspondence Related to G...

FDA Revokes Sublocade Orphan Drug Designation

[ Price : $8.95]

FDA revokes its orphan drug designation for Indiviors Sublocade because it was improperly granted.

Baraclude Label Updated with Safety Study Results

[ Price : $8.95]

FDA approves changes to Baraclude labeling to report data from a post-marketing safety study.

Changes in Special 510(k) Guidance

[ Price : $8.95]

CDRH regulatory advisor Joshua Silverstein tells a Webinar what changes were made to the final Special 510(k) guidance in response...

EIP Pharma Fast Track for Dementia Drug

[ Price : $8.95]

FDA grants EIP Pharma a Fast Track designation for neflamapimod as a treatment for dementia with Lewy bodies.

Comments Sought on Post-market Surveillance Practices

[ Price : $8.95]

Federal Register notice: FDA seeks comments on a draft document that details best practices for drug safety surveillance.

Senator Probing Drug Shortages, Prices

[ Price : $8.95]

Michigan Sen. Gary Peters say he intends to investigate solutions to increasing drug prices and drug shortages.

ASCA Pilot Should Help Device Premarket Review: CDRH

[ Price : $8.95]

CDRHer Stacy Cho outlines elements in a draft guidance to create an Accreditation Scheme for Community Assessment pilot program.